Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.

Winrevair (sotatercept-csrk)

The FDA approved Winrevair (sotatercept-csrk) on March 26, 2024 to treat pulmonary arterial hypertension.

Brand name: Winrevair
Generic name: sotatercept-csrk
FDA approval date: March 26, 2024
Approved use (FDA wording): To treat pulmonary arterial hypertension
Category on this site: Heart & blood

Official sources

FDA novel drug approvals list
FDA announcement

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.